BioBlast Pharma Augments Leadership Team

BioBlast Pharma Ltd., a clinical-stage biotechnology company developing therapies for patients with rare and ultra-rare genetic diseases, has appointed Theresa Stevens to the newly-created position of chief corporate development officer (CCDO). Ms. Stevens will be a member of BioBlast’s executive committee and will oversee, in particular, the corporate strategy, M&A, and business development of marketed and development stage in- and out-licensing.

“I’m thrilled to have Terri join our executive team given her impressive global experience in corporate strategy, M&A, and business development,” said Colin Foster, president and chief executive officer, BioBlast. “With our expansive drug product portfolio and pioneering efforts in a number of orphan disease arenas we have significant potential to accelerate and create value for patients and shareholders through our corporate development efforts.”

Ms. Stevens brings over 29 years of leadership and operational experience in strategy, corporate and business development, and legal, most recently, as president and CCDO of Lupin. Previous to that, she was senior vice president and CCDO of Aptalis Pharma where she led the acquisitions of Eurand and MPex, then led the M&A process that resulted in the sale of Aptalis to Forest Labs for $2.9 billion. She spent 10 years at Novartis both in the U.S. and in Switzerland where she was vice president business development and licensing leading the Pharma General Medicines BD&L negotiating team.